New iron-containing phosphate-binding agents for the correction of hyperphosphatemia in patients with chronic kidney disease


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

This review summarizes the information about the new iron-containing phosphate-binding agents with equal efficacy and safety to other phosphate binders. The iron oxyhydroxide (Velphoro) reduces the serum phosphorus levels, the significantly reduces pill burden, improving the compliance of patients to therapy and its results, and iron citrate increases the body iron stores, reducing the cost of treatment of anemia in patients with ckd.

Texto integral

Acesso é fechado

Bibliografia

  1. O’Seaghdha C.M., Hwang S.J., Muntner P. et al. Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant. 2011; 26(9): 2885-2890.
  2. Zoccali C., Ruggenenti P., Perna A. et al. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition. J Am Soc Nephrol. 2011; 22(10): 1923-1930.
  3. Giacelli C. The emerging role of phosphate in vascular calcification. Kidney Int. 2009; 75(9): 890-897.
  4. Eddington H., Hoefield R., Sinha S. et al. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010; 5(12): 2251-2257.
  5. Kestenbaum B., Sampron J.N., Rudser K.D. et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005; 16(2): 520-528.
  6. Dhingra R., Sullivan L.M., Fox C.S. et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007; 167(9): 879-885.
  7. Isakova T., Wahl P., Vargas G.S. et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011; 79(12): 1370-1378.
  8. Locatelli F., Del Vecchio L. Optimal phosphate control: still an unmet need in chronic kidney disease patients. Expert Opin Pharmacother. 2014; 15(3): 307-309.
  9. Block C.A., Wheeler D.C., Persky M.S. et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012; 23(8): 1407-1415.
  10. Geisser P., Philipp E. Adsorbens für Phosphat aus wässrigem Medium, dessen herstellung und verwendung. German Pat Appl. 1995; DE 195 47 356 A1.
  11. Hergesell O., Ritz E. Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant. 1999; 14(4): 863-867.
  12. Geisser P., Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol. 2010; 74(1): 4-11.
  13. Wüthrich R., Chonchol M., Covic A. et al. Randomized clinical trial ofthe iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol. 2013; 8(2): 280-289.
  14. Floege J., Covic A., Ketteler M. et al. A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients. Kidney Int. 2014; 86(3): 638-647.
  15. Covic A., Floege J., Ketteler M. et al. Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrol Dial Transplant. 2016 Jun 23; pii: gfw242.
  16. Daugirdas JT, Finn WF, Emmett M, Chertow GM. Frequent Hemodialysis Network Trial Group. The phosphate binder equivalent dose. Semin Dial. 2011; 24(1): 41-49.
  17. Ficociello L., Ma L., Parameswaran V. et al. Real-world use of sucroferric oxyhydroxide and hemodialysis patients: Changes in the serum phosphorus control and phosphate binder pill burden. 2015; Poster presented at American Society of Nephrology Annual Meeting 2015. Abstract 37.
  18. Battistella M., Fleites R., Wong R., Jassal S.V. Development, validation, and implementation of a medication adherence survey to seek a better understanding of the hemodialysis patient. Clin Nephrol. 2016; 85(1):12-22.
  19. Yang W., Yang C., Hou C. et al. An open-label, crossover study of a new phosphate-binding agent in haemodialysis patients: ferric citrate. Nephrol Dial Transplant. 2002; 17(2): 265-270.
  20. Gupta A. Ferric citrate hydrate as a phosphate binder and risk of aluminum toxicity. Pharmaceuticals (Basel). 2014; 7(10): 990-998.
  21. Sinsakul M., Sika M., Koury M. et al. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract. 2012; 121(1-2): c25-29.
  22. Dwyer J., Sika M., Schulman G. et al. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis. 2013; 61(5): 759-766.
  23. Yokoyama K., Hirakata H., Akiba T. et al. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol. 2014; 9(3): 543-552.
  24. Lewis J., Sika M., Koury M. et al. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol. 2015; 26(2): 493-503.
  25. Mutell R., Rubin J.L., Bond T.C., Mayne T. Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model. Int J Nephrol Renovasc Dis. 2013; 6: 79-87.
  26. Thomas A, Peterson LE. Reduction of costs for anemia-management drugs associated with the use of ferric citrate. Int J Nephrol Renovasc Dis. 2014; 7: 191-201.
  27. Iida A., Kemmochi Y., Kakimoto K. et al. Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification. Am J Nephrol. 2013; 37(4): 346-358.
  28. Phan O., maillard M., Peregaux C. et al. PA21, a new iron-based noncalcium phosphate binder, prevents vascular calcification in chronic renal failure rats. J Pharmacol Exp Ther. 2013; 346(2): 281-289.
  29. Deger S.M., Erten Y., Pasaoglu O.T. et al. The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients. Clin Exp Nephrol. 2013; 17(3): 416-423.
  30. Block G.A., Fishbane S., Rodriguez M. et al. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5. Am J Kidney Dis. 2015; 65(5): 728-736.
  31. Cernaro V., Santoro D., Lucisano S. et al. The future of phosphate binders: a perspective on novel therapeutics. Expert Opin Investig Drugs. 2014; 23(11): 1459-1463.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar